Clinical Trials
12 trialsNCT03935893 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT02479698 2026-05-20
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT02978625 2026-05-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03304639 2026-05-13
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT05947500 2026-05-13
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT05583708 2026-04-22
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT07387198 2026-04-17
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Not yet recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04792073 2026-04-07
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting